Can we predict who will benefit most from biologics in severe asthma? A post-hoc analysis of two phase 3 trials
Abstract Background Individualized prediction of treatment response may improve the value proposition of advanced treatment options in severe asthma. This study aimed to investigate the combined capacity of patient characteristics in predicting treatment response to mepolizumab in patients with seve...
Main Authors: | Wenjia Chen, Helen K. Reddel, J Mark FitzGerald, Richard Beasley, Christer Janson, Mohsen Sadatsafavi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-05-01
|
Series: | Respiratory Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12931-023-02409-2 |
Similar Items
-
Severe asthma remaining well‐controlled after mepolizumab discontinuation: A case report and literature review
by: Takahiro Matsuyama, et al.
Published: (2023-06-01) -
Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab
by: Carpagnano GE, et al.
Published: (2019-03-01) -
Effect of the SARS-CoV-2 pandemic on treatment processes of patients with severe asthma who were managed with monoclonal antibody
by: Emel Atayık, et al.
Published: (2022-10-01) -
Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience
by: Giulia Scioscia, et al.
Published: (2023-06-01) -
Extension of mepolizumab injection intervals as potential of saving costs in well controlled patients with severe eosinophilic asthma
by: Georg Bölke, MD, et al.
Published: (2022-10-01)